Biohaven's BHV-1400 Shows Promising Results in Phase 1 Trial for IgA Nephropathy

Published 1 days agoBHVN

Biohaven's BHV-1400 Shows Promising Results in Phase 1 Trial for IgA Nephropathy

Biohaven Pharmaceuticals has recently announced encouraging results from its Phase 1 trial of BHV-1400, an innovative treatment for IgA nephropathy (IgAN). The trial demonstrated that a single 125 mg dose of BHV-1400 achieved a median reduction of 60% in levels of galactose-deficient IgA1 (Gd-IgA1) within just four hours, with reductions exceeding 70% at eight hours. These effects were maintained for several days, indicating the potential effectiveness of this treatment in reducing harmful antibodies linked to IgAN.

According to Biohaven, BHV-1400 targets and degrades the pathogenic Gd-IgA1 antibodies while preserving normal immunoglobulins such as IgG, IgA, IgE, and IgM. This selective targeting approach aims to minimize potential disruptions to the immune system. Importantly, the trial results showed no clinically significant changes in either the innate or adaptive immune systems, as assessed by parameters like white blood cells and overall immunoglobulin levels. Additionally, there were no major adverse effects observed in liver function or cholesterol levels when compared to baseline.

Biohaven is gearing up for the next phase of development, with plans to initiate a pivotal trial for IgA nephropathy. They intend to utilize an accelerated regulatory pathway once the Phase 1 study is concluded. Reuters highlighted that this strategy reflects Biohaven's commitment to advancing treatment options for conditions like IgA nephropathy, which currently lacks targeted therapies, potentially reducing the disease's progression to kidney failure.

Share this article

Twitter Facebook LinkedIn

Recent Articles

Blackstone Targets $1 Trillion in Private Wealth Assets

Blackstone Targets $1 Trillion in Private Wealth Assets

25 minutes agoBX

Blackstone’s Global Head of Private Wealth Solutions, Joan Solotar, has laid out an ambitious target as the firm aims to expand its private wealth division to manage $1 trillion in assets. The division has seen rapid growth, currently boasting $233 billion in assets under management within five years, a substantial rise from $58 billion, according to Business Insider. The asset management giant is strategically expanding its reach in key Asian markets such as Japan, Australia, India, and South Korea. These regions are pivotal as Blackstone seeks to tap into the growing wealth of high-net-worth individuals, Moneystreetnews.com reported. The company is tailoring its offerings with semi-liquid products in real estate, private credit, and private equity to attract individual investors looking for alternative investment opportunities. Blackstone is also focusing on education, helping investors and advisors better understand private market investments. As the firm continues its global leadership, it managed a total of $1.06 trillion in assets as of March 31, 2024, with the private wealth segment contributing $241 billion. Their efforts highlight a commitment to expanding their influence in private wealth solutions worldwide.

EssilorLuxottica Expands in Med-Tech and AI with Key Acquisitions

EssilorLuxottica Expands in Med-Tech and AI with Key Acquisitions

40 minutes agoEL

EssilorLuxottica has not announced any plans to acquire Optegra or delve into medical AI as of May 30, 2025. However, the company has been actively enhancing its med-tech and AI footprint through several strategic acquisitions in recent months. In February 2025, EssilorLuxottica acquired Cellview Imaging Inc., a Canadian start-up known for its innovative retinal imaging diagnostics, adding to their collection of ophthalmic instruments. Back in December 2024, they entered an agreement to acquire the Italy-based Espansione Group, which specializes in non-invasive devices for diagnosing and treating eye diseases. Earlier, in July 2024, EssilorLuxottica also secured an 80% stake in Germany's Heidelberg Engineering, a leader in diagnostic solutions and digital surgical technologies within the ophthalmology sector. Additionally, in January 2025, they acquired Pulse Audition, a French start-up focused on AI-based noise reduction and voice enhancement technologies, broadening their influence in hearing solutions. These acquisitions underscore EssilorLuxottica’s strategic aim to advance its capabilities in medical technology and artificial intelligence. By bringing these innovative companies under its umbrella, EssilorLuxottica is strengthening its position in the vision care industry, reflecting a clear commitment to integrating cutting-edge technology into its operations. Reuters reported these moves as part of a broader effort to meet increasing demands in the med-tech landscape.

Synopsys Stops China Sales in Response to U.S. Export Restrictions

Synopsys Stops China Sales in Response to U.S. Export Restrictions

55 minutes agoSNPS

Synopsys, a major player in the semiconductor design software sector, has put a halt on all sales and services to China following new U.S. export restrictions. As of May 29, 2025, Synopsys instructed its Chinese branches to cease any sales and stop processing new orders, complying with the directive from the U.S. Bureau of Industry and Security, which stipulates that shipments to China require a license. This development significantly affects the electronic design automation market, where Synopsys, along with competitors Cadence and Siemens EDA, holds considerable influence. Chinese semiconductor companies rely heavily on the tools provided by these U.S. firms to develop chips. According to Reuters, Synopsys has a notable market share in China, making this suspension impactful on the local industry's access to critical technology. In light of these restrictions, Synopsys has also paused its financial predictions for both annual and quarterly performance, citing unpredictability brought about by the recent changes. Additionally, the company has ensured compliance with the export controls by disabling Chinese clients’ access to its SolvNetPlus support platform. This move reflects broader efforts by the U.S. to limit China's reach into essential semiconductor technologies, further intensifying trade tensions between the two nations.

Richard Montañez Loses Legal Battle Over Flamin' Hot Cheetos Claim

Richard Montañez Loses Legal Battle Over Flamin' Hot Cheetos Claim

Richard Montañez, the former PepsiCo and Frito-Lay executive, has lost his lawsuit against the snack giant in which he claimed to have invented Flamin' Hot Cheetos. A U.S. District Judge, John Holcomb, dismissed the case, stating that Montañez failed to provide adequate evidence that PepsiCo intentionally avoided crediting him for the creation of the popular spicy snack or defamed him by withholding support for a documentary unless it refuted his claim, Reuters reported. Montañez had asserted that he developed the concept for Flamin' Hot Cheetos in the late 1980s after experimenting with seasonings inspired by elote, a traditional roasted Mexican street corn. However, the court found Montañez's public profile required him to meet the 'actual malice' standard for defamation, which involves proving a knowing falsehood or reckless disregard for the truth. Frito-Lay has previously contested his narrative, labeling it an 'urban legend' as noted in a 2021 Los Angeles Times article. Despite this setback, Montañez's story has captured public attention, as reflected in his books and the 2023 film 'Flamin’ Hot,' directed by Eva Longoria. Montañez, who began his career as a janitor before rising to the position of Vice President of Multicultural Marketing at Frito-Lay, argued that the controversy has negatively impacted his professional engagements and potential income opportunities.